Ventyx Biosciences, Inc. (NASDAQ:VTYX) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX) have been given a consensus recommendation of “Moderate Buy” by the five ratings firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price objective among brokers that have issued a report on the stock in the last year is $10.00.

A number of equities analysts recently commented on the company. Canaccord Genuity Group cut their price objective on Ventyx Biosciences from $15.00 to $14.00 and set a “buy” rating on the stock in a research note on Monday, August 12th. HC Wainwright reaffirmed a “neutral” rating and issued a $6.00 price objective on shares of Ventyx Biosciences in a research note on Monday, November 11th. Oppenheimer reaffirmed an “outperform” rating and issued a $9.00 price objective (down from $10.00) on shares of Ventyx Biosciences in a research note on Friday, November 8th. Finally, Wells Fargo & Company cut their price objective on Ventyx Biosciences from $16.00 to $11.00 and set an “overweight” rating on the stock in a research note on Monday, August 12th.

Ventyx Biosciences Trading Up 0.6 %

Shares of VTYX stock opened at $1.73 on Friday. The business’s 50-day moving average price is $2.20 and its 200-day moving average price is $2.70. The firm has a market capitalization of $122.33 million, a price-to-earnings ratio of -0.73 and a beta of 0.37. Ventyx Biosciences has a 12 month low of $1.67 and a 12 month high of $11.48.

Hedge Funds Weigh In On Ventyx Biosciences

Several institutional investors have recently added to or reduced their stakes in the business. Deerfield Management Company L.P. Series C lifted its stake in Ventyx Biosciences by 64.6% in the second quarter. Deerfield Management Company L.P. Series C now owns 5,829,570 shares of the company’s stock valued at $13,466,000 after buying an additional 2,287,570 shares during the period. Farallon Capital Management LLC acquired a new position in Ventyx Biosciences in the first quarter valued at approximately $17,435,000. Redmile Group LLC lifted its stake in Ventyx Biosciences by 944.4% in the first quarter. Redmile Group LLC now owns 2,164,126 shares of the company’s stock valued at $11,903,000 after buying an additional 1,956,923 shares during the period. Sio Capital Management LLC increased its holdings in shares of Ventyx Biosciences by 153.2% during the third quarter. Sio Capital Management LLC now owns 1,971,948 shares of the company’s stock valued at $4,299,000 after acquiring an additional 1,193,024 shares in the last quarter. Finally, Vestal Point Capital LP increased its holdings in shares of Ventyx Biosciences by 31.2% during the third quarter. Vestal Point Capital LP now owns 1,725,000 shares of the company’s stock valued at $3,760,000 after acquiring an additional 410,000 shares in the last quarter. 97.88% of the stock is owned by institutional investors and hedge funds.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.